Drug Trial Radar · NCT01039948
A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Apr 8, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
203
Actual
Start
Dec 2009
Primary completion
Aug 2013
Study completion Aug 2013
Sponsor
- Lead sponsor
- AVEO Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 25, 2009
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
During Phase 1b portion, there will be a dose-escalation of AV-299 (formerly SCH 900105) in combination with the recommended dose of gefitinib in subjects with NSCLC or advanced solid tumor. The objective is to determine the safety, tolerability, dose limiting toxicity (DLT) and recommended Phase 2 dose (RP2D) in combination with gefitinib for the Phase 2 portion. The Phase 2 is an open-label, 2-arm, randomized study designed to compare the combination of AV-299 (formerly SCH900105) and gefitinib versus gefitinib alone in clinically selected Asian subjects with previously untreated lung adenocarcinoma who have a high likelihood of harboring activating EGFR mutations. Subjects who progress after initial disease control in the gefitinib alone arm may crossover to the combination arm.
Conditions
- Carcinoma, Non-Small Cell-Lung
- Lung Neoplasms
- Lung Cancer
- Respiratory Tract Neoplasms
Interventions
AV-299 + gefitinibBiological
AV-299 is a humanized anti-HGF IgG1 monoclonal antibody directed against free HGF, ligand for c-Met tyrosine kinase receptor.
GefitinibDrug
Gefitinib is a small molecule (drug) which selectively inhibits epidermal growth factor receptor's (EGFR) tyrosine kinase domain.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ib: Dose Limiting Toxicity and Recommended Phase II DoseTime frame: Every 4 weeks for the first 4 months of treatment period, every 8 weeks thereaftert
- Phase 2: Objective Response RateTime frame: Every 4 weeks for the first 4 months of treatment period, every 8 weeks thereafter
Locations
26 sites in 7 countries. Site status is shown where the registry gives one.
Investigational Site 1
Shatin N.T., Hong Kong
Investigational Site 10
Kuala Lumpur, Malaysia
Investigational Site 9
Kuala Lumpur, Malaysia
Investigational Site 11
Kuala Pahang, Malaysia
Investigational Site 12
Manila, Philippines
Investigational Site 13
Pasig, Philippines
Investigational Site 14
Quezon City, Philippines
Investigational Site 15
Singapore, Singapore
Investigational Site 2
Chungcheongbuk-do, South Korea
Investigational Site 3
Gyeonggi-do, South Korea
Investigational Site 4
Jeollanam-do, South Korea
Investigational Site 5
Seoul, South Korea
Investigational Site 6
Seoul, South Korea
Investigational Site 7
Seoul, South Korea
Investigational Site 8
Seoul, South Korea
Investigational Site 16
Changhua, Taiwan
Investigational Site 17
Chiayi City, Taiwan
Investigational Site 18
Taichung, Taiwan
Investigational Site 19
Tainan, Taiwan
Investigational Site 20
Taipei, Taiwan
Investigational Site 21
Taipei, Taiwan
Investigational Site 22
Taoyuan, Taiwan
Investigational Site 23
Bangkok, Thailand
Investigational Site 24
Chiang Mai, Thailand
Investigational Site 25
KhonKaen, Thailand
Investigational Site 26
Songkhla, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.